Table 2.
Outcome by NPM1 mutations status and treatment with ATRA.
| Parameter | NPM1 wt. | NPM1 mut. | P value |
|---|---|---|---|
| Total no. | 50 | 20 | |
| ATRA | 29 (58) | 7 (35) | 0.07 |
| No ATRA | 21 (42) | 13 (65) | |
| Response rate | |||
| ATRA | 19 (66) | 5 (71) | 0.08 |
| No ATRA | 11 (52) | 9 (69) | |
| 4 weeks mortality | |||
| ATRA | 5 (17) | 1 (14) | 0.34 |
| No ATRA | 4 (18) | 3 (23) | |
| 8 weeks mortality | |||
| ATRA | 8 (28) | 1 (14) | 0.11 |
| No ATRA | 6 (28) | 5 (38) | |
| Median OS (weeks) | |||
| ATRA | 52 (1–684) | 41 (3–452) | 0.78 |
| No ATRA | 41 (2–360) | 60 (1–735) | |
| Median EFS (weeks) | |||
| ATRA | 30 (1–684) | 34 (3–176) | 0.18 |
| No ATRA | 18 (2–232) | 31 (1–650) | |
| Median RFS (weeks) | |||
| ATRA | 41 (15–680) | 82 (10–173) | 0.21 |
| No ATRA | 37 (9–228) | 56 (1–646) |
NPM1, nucleophosmin; WT, wild type; mut, mutated; ATRA, all-trans retinoic acid; OS, overall survival; EFS, event-free survival; RFS, relapse-free survival.